With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and closer collaboration between healthcare professionals.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on ...

Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

The pivotal trial that established sildenafil as a treatment for WHO Group 1 PH was ... functional class did not significantly differ at any dose. Only the 40-mg dose improved incidence and ...

No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has potential in treating idiopathic pulmonary ... need for a new treatment ...

Get Instant Summarized Text (Gist) Mindfulness practice is linked to reduced anxiety, breathlessness, fatigue, and insomnia in individuals with chronic obstructive pulmonary disease (COPD). The ...

(RTTNews) - Tenax Therapeutics, Inc. (TENX) announced an expansion of its Phase 3 LEVEL program for TNX-103 or oral levosimendan, a novel treatment for pulmonary ... and no new safety concerns.